Adagen
Severe Combined Immunodeficiency
Leadiant Biosciences, Inc.UNKNOWNPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
14 Active assets in the Severe Combined Immunodeficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2/3 | BB |
Nivestim National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | BB |
Alemtuzumab Washington University School of Medicine | Phase 2/3 | BB |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 2/3 | BB |
Busulfanum National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2/3 | BB |
View all 30 →
Same molecule, other indications
Adagen is also rated in:
severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiencyDormant
BB
Indicative · Phase 3
64 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →